



**\*Defined as:**

- Hematopoietic stem cell transplant patients in the first 24 months after transplant
- Patients with neutrophil count < 0.5 x 10<sup>9</sup>/ L for duration ≥ 48 hours
- Patients receiving corticosteroid therapy equivalent to prednisone ≥ 20mg/day for duration of ≥ two weeks
- HIV positive patients with CD4 < 200 x 10<sup>6</sup>/ L
- Patients with inflammatory bowel disease, rheumatologic conditions, multiple sclerosis, or solid organ recipients receiving immunosuppressive therapy, such as, infliximab, etanercept, and methotrexate
- Oncology patients receiving chemotherapy
- Oncology patients receiving active radiation other than internal radiation (e.g. brachytherapy) or radiation therapy limited to very small focused areas (e.g. for localized skin cancers)
- Patients with extensive loss of skin/mucous membrane barrier defenses e.g., graft versus host disease, Steven-Johnson syndrome, scalded skin syndrome, major burns
- Patients with congenital or acquired hypogammaglobinemia or agammaglobinemia, severe combined immunodeficiency or other congenital immune deficiency syndrome

Ref: <https://albertahealthservices.ca/assets/healthinfo/ipc/hi-ipc-immunocompromised-patients.pdf>

**\*\*Unless precautions are indicated for other infectious conditions**